Product Detail
Product NameVDR antibody
Host SpeciesRabbit
ClonalityPolyclonal
PurificationAntibodies were purified by affinity purification using immunogen.
ApplicationsWB,IHC,IF
Species ReactivityHuman,Mouse,Rat
SpecificityThe antibody detects endogenous level of total VDR protein.
Immunogen TypeRecombinant Protein
Immunogen DescRecombinant protein of human VDR.
Target NameVDR
ConjugateUnconjugated
Other NamesVDR; NR1I1; Vitamin D3 receptor; 1;25-dihydroxyvitamin D3 receptor; Nuclear receptor subfamily 1 group I member 1;
Accession NoSwiss-Prot#: P11473
NCBI Gene ID: 7421
Uniprot
P11473
Gene ID
7421;
Sdspage MW48kd
Concentration1.0mg/ml
FormulationSupplied at 1.0mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
StorageStore at -20˚C
Application Details
WB 1:500 - 1:2000
IHC 1:50 - 1:200
IF 1:50 - 1:100
Western blot analysis of extracts of mouse kidney, using VDR at 1:1000 dilution.
The vitamin D receptor (VDR), also known as the calcitriol receptor, and also known as NR1I1 (nuclear receptor subfamily 1, group I, member 1), is a member of the nuclear receptor family of transcription factors. Upon activation by vitamin D, the VDR forms a heterodimer with the retinoid-X receptor and binds to hormone response elements on DNA resulting in expression or trans-repression of specific gene products.It is an intracellular hormone receptor that specifically binds 1,25(OH)2D3 and mediates its effects. Downstream targets of this nuclear hormone receptor are principally involved in mineral metabolism though the receptor regulates a variety of other metabolic pathways, such as those involved in the immune response and cancer. Defects in VDR are the cause of rickets vitamin D-dependent type 2A (VDDR2A). A disorder of vitamin D metabolism results in severe rickets, hypocalcemia and secondary hyperparathyroidism. Most patients have total alopecia in addition to rickets. This antibody is a rabbit Primary antibodyto human VDR.
If you have published an article using product 38397, please notify us so that we can cite your literature.
et al,Discovery of vitexin as a novel VDR agonist that mitigates the transition from chronic intestinal inflammation to colorectal cancer. In Mol Cancer on 2024 Sep 13 by Yonger Chen, Jian Liang,et al..PMID:39272040
, (2024),
PMID:
39272040
The lead time is currently 2 weeks.
